277 related articles for article (PubMed ID: 35800367)
1. Role of prostate cancer stem-like cells in the development of antiandrogen resistance.
Kushwaha PP; Verma S; Kumar S; Gupta S
Cancer Drug Resist; 2022; 5(2):459-471. PubMed ID: 35800367
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.
Ojo D; Lin X; Wong N; Gu Y; Tang D
Cancers (Basel); 2015 Nov; 7(4):2290-308. PubMed ID: 26593949
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.
Huang H; Wang C; Liu F; Li HZ; Peng G; Gao X; Dong KQ; Wang HR; Kong DP; Qu M; Dai LH; Wang KJ; Zhou Z; Yang J; Yang ZY; Cheng YQ; Tian QQ; Liu D; Xu CL; Xu DF; Cui XG; Sun YH
Clin Cancer Res; 2018 Sep; 24(18):4612-4626. PubMed ID: 29691294
[No Abstract] [Full Text] [Related]
5. Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics.
Verma S; Shankar E; Kalayci FNC; Mukunda A; Alassfar M; Singh V; Chan ER; MacLennan GT; Gupta S
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339129
[TBL] [Abstract][Full Text] [Related]
6. The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges.
Yun EJ; Lo UG; Hsieh JT
Asian J Urol; 2016 Oct; 3(4):203-210. PubMed ID: 29264188
[TBL] [Abstract][Full Text] [Related]
7. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
Bourguignon LY; Wong G; Earle C; Chen L
J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
[TBL] [Abstract][Full Text] [Related]
9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
10. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
Tilki D; Schaeffer EM; Evans CP
Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell in prostate cancer progression, metastasis and therapy resistance.
Verma P; Shukla N; Kumari S; Ansari MS; Gautam NK; Patel GK
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188887. PubMed ID: 36997008
[TBL] [Abstract][Full Text] [Related]
12. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
13. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
15. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
[TBL] [Abstract][Full Text] [Related]
16. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer.
Rice MA; Malhotra SV; Stoyanova T
Front Oncol; 2019; 9():801. PubMed ID: 31555580
[TBL] [Abstract][Full Text] [Related]
17. Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.
Federer-Gsponer JR; Müller DC; Zellweger T; Eggimann M; Marston K; Ruiz C; Seifert HH; Rentsch CA; Bubendorf L; Le Magnen C
Prostate; 2020 Sep; 80(13):1108-1117. PubMed ID: 32628318
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives.
Pinto F; Dibitetto F; Ragonese M; Bassi P
Med Sci (Basel); 2022 Apr; 10(2):. PubMed ID: 35645241
[TBL] [Abstract][Full Text] [Related]
19. Autophagic homeostasis is required for the pluripotency of cancer stem cells.
Sharif T; Martell E; Dai C; Kennedy BE; Murphy P; Clements DR; Kim Y; Lee PW; Gujar SA
Autophagy; 2017 Feb; 13(2):264-284. PubMed ID: 27929731
[TBL] [Abstract][Full Text] [Related]
20. NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis.
Jeter CR; Liu B; Lu Y; Chao HP; Zhang D; Liu X; Chen X; Li Q; Rycaj K; Calhoun-Davis T; Yan L; Hu Q; Wang J; Shen J; Liu S; Tang DG
Cell Discov; 2016; 2():16041. PubMed ID: 27867534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
